Stock CVKD CADRENAL THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Cadrenal Therapeutics, Inc.

Equities

CVKD

US1276361086

Market Closed - Nasdaq
Other stock markets
 21:30:00 23/05/2024 BST 		5-day change 1st Jan Change
0.419 USD +1.53% Intraday chart for Cadrenal Therapeutics, Inc. -2.58% -43.37%
05-09 Cadrenal Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-09 Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts CI

Evolution of the average Target Price on Cadrenal Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

576c5401331e43207bb2.Ezo2vwgQ9gvLoYNpu8CVRiON7G6DKTjzooDGTgc7pNM.YF5M0yVSo3ui1soM2ZKmCRD3rlaxG3qh9biHf1JJ7rZ-aHPzOmOEMrzC8A~cbc2f386a35fdd51b4a36a04c04795fd

Analyst Recommendations on Cadrenal Therapeutics, Inc.

Noble Capital Starts Cadrenal Therapeutics With Outperform Rating, $4 Price Target MT
HC Wainwright Initiates Cadrenal Therapeutics With Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.419 USD
Average target price
3.5 USD
Spread / Average Target
+735.32%
High Price Target
4 USD
Spread / Highest target
+854.65%
Low Price Target
3 USD
Spread / Lowest Target
+615.99%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Cadrenal Therapeutics, Inc.

Noble Capital
HC Wainwright

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CVKD Stock
  4. Consensus Cadrenal Therapeutics, Inc.